ACR/EULAR 2010: The classification criteria for definite Rheumatoid Arthritis. Score ≥ 6 is diagnostic.
Select Categories
Select one option from each category to calculate the ACR/EULAR 2010 classification score.
Guidelines & Evidence
Verified
Last Review: 2026-07-17
When to Use
When to Use
Classification of adult patients with suspected rheumatoid arthritis
Evaluating patients with at least one joint with definite clinical synovitis (swelling)
Standardising clinical trial enrolment and early DMARD initiation
Differentiating RA from other inflammatory arthritides
Guiding early intervention to prevent irreversible joint damage
Prerequisites
The criteria should only be applied if synovitis is not better explained by another disease (e.g., SLE, Psoriatic Arthritis, Gout, CPPD). If the patient has typical erosions on X-ray, RA can be classified without further scoring.
Patient Population
Adults presenting with new-onset inflammatory arthritis. The criteria are designed to identify patients who would benefit from early DMARD therapy, prioritising sensitivity over the older 1987 criteria which favoured specificity and late-stage disease.
How it Works
Joint Involvement (0–5 pts)
| 1 large joint | 0 pts |
| 2–10 large joints | 1 pt |
| 1–3 small joints (with or without large) | 2 pts |
| 4–10 small joints (with or without large) | 3 pts |
| > 10 joints (at least 1 small joint) | 5 pts |
Serology (0–3 pts)
| Negative RF and negative ACPA | 0 pts |
| Low-positive RF or low-positive ACPA | 2 pts |
| High-positive RF or high-positive ACPA | 3 pts |
Acute-Phase Reactants (0–1 pt)
| Normal CRP and normal ESR | 0 pts |
| Abnormal CRP or abnormal ESR | 1 pt |
Duration of Symptoms (0–1 pt)
| < 6 weeks | 0 pts |
| ≥ 6 weeks | 1 pt |
Interpretation
Total score ≥ 6/10 = classified as "Definite RA". "High-positive" serology is defined as > 3 × the upper limit of normal (ULN). "Low-positive" is any positive result ≤ 3 × ULN.
Clinical Pearls
Diagnostic Shift
Unlike the 1987 criteria, which prioritised chronic, erosive disease (late-stage RA), the 2010 criteria focus on early detection to prevent joint damage. The inclusion of ACPA was the most significant biological advancement, as it has superior specificity (~95%) and prognostic value for radiographic progression compared to Rheumatoid Factor.
Small vs. Large Joints
Small joints: MCP, PIP, MTP (2–5), thumb IP, and wrists (counted as a small joint)
Large joints: Shoulders, elbows, hips, knees, and ankles
DIP joints, 1st MTP, and 1st CMC joints are excluded (more suggestive of OA)
Limitations
Seronegative RA (negative RF/ACPA) requires high joint counts to reach the threshold
May misclassify other inflammatory arthritides if exclusions are not rigorously applied
Does not account for symmetric vs. asymmetric patterns, though RA is typically symmetric
Joint involvement scoring can be ambiguous in patients with prior joint surgery or trauma
Next Steps
Score ≥ 6 (Classified as RA)
01
Initiate DMARD therapy (methotrexate is first-line unless contraindicated)
02
Screen for comorbidities (CVD risk, osteoporosis, interstitial lung disease)
03
Set treat-to-target goals (remission or low disease activity)
04
Obtain baseline hand/foot radiographs to monitor for future erosions
05
Consider early combination therapy for high-risk patients (seropositive + high joint counts)
Score < 6 (Not Classified)
01
Re-evaluate prospectively if symptoms persist or worsen
02
Consider MSK ultrasound or MRI to detect subclinical synovitis
03
Review differential diagnosis (viral arthritis, spondyloarthritis, connective tissue disease)
04
Repeat serology in 3–6 months if initial testing was early in symptom onset
Disease Activity Monitoring
DAS28 (disease activity monitoring)
CDAI (Clinical Disease Activity Index)
SDAI (Simplified Disease Activity Index)
The Evidence
Primary Reference
2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.
Aletaha D et al. • Arthritis and Rheumatism. 2010;62(9):2569-81
The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: methodological report phase 2.
Funovits J et al. • Arthritis and Rheumatism. 2010;62(9):2582-91
Origins & History
Consensus Building
The 2010 criteria were developed through a joint ACR/EULAR collaboration using a three-phase approach: a data-driven phase based on actual patient cohorts, a consensus-driven phase using expert scenarios, and a final validation phase. The goal was to shift the paradigm from treating established joint damage to treating early inflammation, enabling earlier DMARD initiation.
Last Comprehensive Review: 2026-07-17